SLC5A2 and metabolic dysfunction-associated steatotic liver disease: While no FDA-approved pharmacologic treatments exist for NAFLD, certain agents such as metformin, GLP-1 receptor agonists, and SGLT-2 inhibitors have shown promise in improving metabolic parameters in patients with coexisting NAFLD and type 2 diabetes (6).